Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure. CEO Allen Cunningham said the new cash comes on the heels of results from a mid-stage obesity study showing treatment with the Rivus drug led to fat loss while also preserving skeletal muscle.
Acumen Pharmaceuticals’ IPO raised $160 million to fund clinical development of its Alzheimer’s disease drug candidate. Though that drug goes after the same target as Biogen’s recently approved Aduhelm, Acumen says its antibody has potential dosing and safety advantages.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The app is based on technology licensed from the University of Virginia Licensing and Ventures Group.
A medical device company has raised nearly $1.3 million to advance a diagnostic to detect life-threatening bleeding and blood clots, according to a Form D filing with the U.S. Securities and Exchange Commission. HemoSonics‘ Point of Care Analyzer evaluates the systems that manage clotting: platelets, coagulation factors, fibrinogen and fibrinolytic proteins. The device is being […]